DefinePK

Abstract

Objective: The present study was conducted to assess the safety of continuing aspirin during percutaneous nephrolithotomy (PCNL).
Methods: PubMed, CENTRAL, Scopus, Embase, and Web of Science were searched for relevant studies up to 5th February 2025. Random-effects meta-analysis was conducted for change in hemoglobin, blood loss, length of hospital stay, complications, need for transfusion and postoperative thrombotic events between patients continuing aspirin vs patients not on any antithrombotic therapy in the perioperative period (controls).
Results: Six studies were included. Meta-analysis showed no statistically significant difference in change in hemoglobin levels (MD: -0.03 95% CI: -0.24, 0.18 I2=31%), estimated blood loss (MD: -6.91 95% CI: -14.36, 0.54 I2=0%), length of hospital stay (MD: -0.31 95% CI: -0.99, 0.37 I2=94%), all complications (OR: 1.29 95% CI: 0.94, 1.79 I2=0%), serious complications (OR: 1.95 95% CI: 0.88, 4.29 I2=38%), bleeding complications (OR: 1.11 95% CI: 0.71, 1.73 I2=0%), need for transfusion (OR: 1.10 95% CI: 0.62, 1.94 I2=0%), and postoperative thrombotic events (OR: 1.30 95% CI: 0.21, 8.24 I2=36%) between patients continuing aspirin and controls.
Conclusions: Continuing aspirin during the perioperative period may not increase the risk of adverse outcomes of PCNL. However, given the scarce data further prospective and Multi-Centre studies are needed to improve the quality of evidence.
doi: https://doi.org/10.12669/pjms.41.7.12240
How to cite this: Hua L, Zhou H. The efficacy of continuing aspirin in the perioperative period during percutaneous nephrolithotomy: A systematic review and meta-analysis. Pak J Med Sci. 2025;41(7):2092-2100. doi: https://doi.org/10.12669/pjms.41.7.12240
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.